English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
In 2019, owing to the failure to meet the desired endpoints, two big pharma players, Abbvie and Biogen announced their decision to terminate the development of their pipeline anti-tau antibodies for PSP, namely ABBV-8E12 and gosuranemab, respectively.
In 2019, owing to the failure to meet the desired endpoints, two big pharma players, Abbvie and Biogen announced their decision to terminate the development of their pipeline anti-tau antibodies for PSP, namely ABBV-8E12 and gosuranemab, respectively.
·3Кб Просмотры
·0 предпросмотр